Rapamycin Synthesis via Silyl Ether Protecting Group
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing everolimus suffer from low yields and significant formation of undesired by-products, requiring complex and costly processes with unstable reagents and multiple purification steps.
Innovation Solution
A method involving the reaction of ethylene oxide with a tri-substituted silyl triflate to produce 2-(tri-substituted silyl)oxyethyl triflate, which is then reacted with rapamycin in the presence of an organic base to form a protected derivative, followed by deprotection to obtain everolimus, simplifying the synthesis and improving yields.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If known methods using protected 2-hydroxyethyl fluoroalkylsulfonate are used for alkylation of rapamycin, then everolimus can be synthesized, but the overall yield is low (17-52%) and significant formation of undesired by-products occurs
Solution Approach 1:
The patent introduces an intermediary compound - the silyl ether protecting group (specifically t-butyldimethylsilyl or t-butyldiphenylsilyl groups) - that mediates the alkylation reaction. This protecting group enables selective alkylation at the C40-hydroxyl position while preventing unwanted side reactions at other positions, thereby reducing by-product formation and improving overall yield to 67-73%.
Solution Approach 2:
The patent changes key reaction parameters including: (1) using excess alkylating reagent (4-8 equivalents instead of the typical stoichiometric amount), (2) performing the reaction at elevated temperature (60-70°C instead of room temperature), and (3) using specific solvents (dichloromethane, ethyl acetate, or toluene). These parameter changes collectively improve the reaction efficiency and yield while maintaining selectivity.
2Stability of the object's composition
If complex two-step synthesis schemes are used to prepare stable alkylating reagents, then reagent stability is improved, but the synthesis process becomes more complex and laborious
Solution Approach 1:
The patent applies preliminary protection of the rapamycin C40-hydroxyl group as a silyl ether before alkylation. This preliminary action prevents unwanted side reactions during the alkylation step, allowing the use of stable, pre-prepared alkylating reagents without requiring complex two-step synthesis schemes. The silyl protecting group remains stable during alkylation and is easily removed in a final deprotection step.
3Productivity
If excess alkylating reagent (4-8 equivalents) is used to improve yield, then productivity increases, but the complexity of the process and cost increase
Solution Approach 1:
The silyl ether protecting group acts as an intermediary that enables the use of excess alkylating reagent without compromising selectivity. The protecting group temporarily blocks other reactive sites on the rapamycin molecule, ensuring that even with 4-8 equivalents of alkylating agent present, alkylation occurs selectively only at the C40 position. This resolves the contradiction by allowing high productivity through excess reagent while maintaining process simplicity through selective protection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves higher yields and reduces the formation of by-products, resulting in a more cost-effective and less laborious process for producing everolimus with improved purity.
Implementation Method 1
preparing a 2-(tri-substituted silyl)oxyethyl triflate of formula 4 by reacting ethylene oxide and a tri-substituted silyl triflate of formula 3
Implementation Method 2
reacting the 2-(tri-substituted silyl)oxyethyl triflate of formula 4 obtained in step (a) with rapamycin in the presence of a molar excess of organic base
Implementation Method 3
deprotecting the protected rapamycin derivative of formula 5 to obtain the rapamycin derivative of formula (I)
Data Source
AI summary
The present invention relates to a method for the production of a rapamycin derivative of formula (I), the method comprising the preparation of a 2-(tri-substituted silyl)oxyethyl triflate by reacting ethylene oxide and a tri-substituted silyl triflate, reaction of the resulting 2-(tri-substituted silyl)oxyethyl triflate with rapamycin in the presence of a molar excess of organic base, and deprotection to obtain the rapamycin derivative of compound (I).